Selpercatinib
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
Selpercatinib
Jun 15, 2024, 14:10 |
Drugs
Vivek Subbiah: FDA granted full traditional approval of RET inhibitor Selpercatinib in RET+ thyroid cancers
Vivek Subbiah shared on LinkedIn: . "FDA granted full traditional…
Apr 14, 2024, 11:39 |
Drugs
Nieves Martinez Lago: FDA approvals Tumor-Agnostic drugs
Nieves Martinez Lago, Medical Oncologist at University Hospital Complex of Ferrol, shared on X/Twitter: "FDA…
Apr 9, 2024, 09:03 |
Insight
Giannis Mountzios: The value of post-marketing pragmatic re-assessment of new TKIs in NSCLC
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General…
Mar 19, 2024, 03:22 |
Blog
Vivek Subbiah: Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic Pancreatic Cancer
Vivek Subbiah shared a post on X/Twitter: ''Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic…
Mar 16, 2024, 10:45 |
Drugs
Vivek Subbiah: Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic Pancreatic Cancer
Vivek Subbiah recently shared a post on X/Twitter: “Exceptional Responses to Selpercatinib in RET Fusion–Driven…
Dec 4, 2023, 15:54 |
Blog
Vivek Subbiah: Tissue-agnostic precision medicine takes the spotlight!
Vivek Subbiah shared a post on his LinkedIn page: "Hot off the press- Friday Motivation!…
Nov 28, 2023, 16:43 |
Drugs
Vivek Subbiah: Pleased to share our review on RET inhibitors
Vivek Subbiah shared on LinkedIn: "Pleased to share our review on RET inhibitors and RET inhibitor…
Aug 25, 2023, 16:32 |
Insight
Vivek Subbiah: Huge win for patients with RET+ thyroid cancers.
Quoting Vivek Subbiah, the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute,…
All:
8
Posts:
1 - 10
Career Journey to President and CEO - OncoInfluencers
New Paper Alert! Long-Term Benefits of Dabrafenib-Trametinib in Stage III Melanoma: 8-Year COMBI-AD Trial Results
We mourn the loss of our Ivy Elkins
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
Rob Winn: Honored to receive the ASCO Allen Lichter Visionary Leader Award
Facebook
RSS Feed
Twitter
Linkedin
Youtube